Lakefront Biotherapeutics (LKFT) vs NewAmsterdam Pharma N.V. (NAMS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Lakefront Biotherapeutics (LKFT) has outperformed NewAmsterdam Pharma N.V. (NAMS) over the past year, gaining 8.6% versus a loss of 51.9%. Over five years, NAMS leads with a +88.0% price change compared with -31.8% for LKFT. NewAmsterdam Pharma N.V. is the larger company by market cap ($2.21 billion vs $2.18 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LKFT | NAMS |
|---|---|---|
| Share price | $33.31 | $18.41 |
| Market cap | $2.18B | $2.21B |
| 1-day change | -0.24% | -5.64% |
| YTD return | +1.87% | -47.52% |
| 1-year return | +8.64% | -51.89% |
| 5-year return | -31.80% | +88.05% |
| P/E ratio (TTM) | 2.39 | — |
| EPS (TTM) | $13.94 | $-1.69 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $22.50M |
| Revenue growth (YoY) | — | -50.61% |
| Net income (latest FY) | — | $-203.82M |
| Operating margin | — | -1002.90% |
| Net margin | — | -905.74% |
| 52-week high | $36.24 | $42.21 |
| 52-week low | $25.68 | $17.90 |
| Distance from 52-week high | -8.08% | -56.38% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | -7.39% | +174.85% |
| Average volume | 280.49K | 1.66M |
| Shares outstanding | 65.48M | 119.93M |
| Employees | 196 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LKFT has outperformed NAMS by 60.5 percentage points over the past year.
About Lakefront Biotherapeutics
LKFT stock →Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
Health Care · Biotechnology: Pharmaceutical Preparations · 196 employees
About NewAmsterdam Pharma N.V.
NAMS stock →NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
LKFT vs NAMS FAQ
Which is bigger, Lakefront Biotherapeutics or NewAmsterdam Pharma N.V.?
NewAmsterdam Pharma N.V. (NAMS) is larger, with a market capitalization of $2.21B compared with $2.18B for Lakefront Biotherapeutics (LKFT).
Which stock has performed better over the past year, LKFT or NAMS?
LKFT returned +8.64% over the past 12 months, compared with -51.89% for NAMS (price return, excluding dividends). Past performance does not predict future results.
Are Lakefront Biotherapeutics and NewAmsterdam Pharma N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.